Range Low Price High Price Comment
30 days $4.82 $6.04 Thursday, 28th Mar 2024 BCRX stock ended at $5.08. This is 1.36% less than the trading day before Wednesday, 27th Mar 2024. During the day the stock fluctuated 5.53% from a day low at $5.06 to a day high of $5.34.
90 days $4.82 $7.75
52 weeks $4.82 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
2021-06-16 $15.50 $16.26 $15.48 $16.08 2 551 944
2021-06-15 $16.15 $16.21 $15.50 $15.61 3 469 741
2021-06-14 $16.70 $16.90 $16.15 $16.28 2 854 145
2021-06-11 $17.20 $17.28 $16.62 $16.71 2 940 536
2021-06-10 $16.97 $17.74 $16.65 $17.21 4 385 350
2021-06-09 $17.18 $17.59 $16.92 $16.99 2 836 180
2021-06-08 $17.30 $17.48 $16.56 $17.04 2 590 767
2021-06-07 $16.37 $17.68 $16.35 $17.24 4 754 006
2021-06-04 $16.42 $16.50 $15.97 $16.29 2 258 578
2021-06-03 $16.30 $16.72 $16.04 $16.36 3 062 160
2021-06-02 $16.00 $16.44 $15.62 $16.30 3 717 683
2021-06-01 $15.88 $16.20 $15.42 $15.95 2 998 475
2021-05-28 $15.04 $16.29 $14.89 $15.77 7 403 640
2021-05-27 $13.65 $15.02 $13.62 $14.75 6 600 962
2021-05-26 $13.28 $13.66 $13.12 $13.61 1 876 312
2021-05-25 $13.62 $13.89 $13.27 $13.28 2 224 253
2021-05-24 $13.92 $14.12 $13.60 $13.62 2 288 255
2021-05-21 $14.10 $14.56 $13.84 $13.86 2 903 031
2021-05-20 $13.98 $14.18 $13.71 $13.97 2 485 819
2021-05-19 $13.89 $14.29 $13.62 $13.98 3 204 035
2021-05-18 $14.27 $14.97 $14.22 $14.38 4 870 571
2021-05-17 $12.81 $14.45 $12.64 $14.38 7 448 032
2021-05-14 $12.06 $13.13 $11.90 $12.84 5 531 208
2021-05-13 $12.51 $12.61 $11.84 $11.96 3 138 322
2021-05-12 $11.90 $12.67 $11.90 $12.49 4 098 271
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT